Andre Forbes, Ph.D.

Senior Computational Scientist at Pathos

Andre Forbes, Ph.D. has extensive experience in computational biology and clinical research. Andre currently works as a Computational Biologist at Pathos since 2023. Prior to that, they were a Senior Computational Biologist at Memorial Sloan Kettering Cancer Center from 2022 to 2023. Andre also worked as a Doctoral Student at Weill Cornell Graduate School of Medical Sciences, specializing in the construction of tissue-specific gene regulatory networks and the development of machine learning methods to analyze genomic data. Before that, they were involved in clinical research at Memorial Sloan Kettering Cancer Center, focusing on data mining and retrospective studies in prostate cancer. Andre started their research career as an Undergraduate Researcher at Georgia Institute of Technology and Cornell University, where they gained experience in synthetic biology and immunohistochemical staining protocols. Additionally, they have worked as an Assistant Laboratory Technician at Holberton Hospital, performing biochemical analysis and immunoassays.

Andre Forbes, Ph.D. pursued their education in the field of Biology and Physiology, Biophysics, and Systems Biology. Andre obtained a Bachelor of Science (B.S.) degree in Biology, General from Morehouse College, where they studied from 2007 to 2011. Building upon their undergraduate studies, Andre went on to complete their Doctor of Philosophy (Ph.D.) in Physiology, Biophysics, and Systems Biology from Weill Cornell Graduate School of Medical Sciences. Andre spent the years 2015 to 2022 pursuing their doctoral degree at this institution.

Location

Brooklyn, United States

Links


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Pathos

Pathos develops an AI-enabled drug discovery platform to reduce the medication development process. Its self-learning platform utilizes big data, technology, and artificial intelligence to identify targets, validate them, and establish their clinical efficacy. It also helps drug developers to explore novel concepts, and advance breakthroughtherapies. The company's OS platform is capable of managing the entire end-to-end process of designing and developing novel therapeutics.


Industries

Employees

1-10

Links